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BACKGROUND: To determine the dose-limiting toxicity (DLT), maximum tolerated dose, recommended dose (RD) and preliminary
evidence of activity of escalating doses of irinotecan (CPT-11) fixed-dose-rate infusional gemcitabine (FDR-GMB) and bevacizumab in
pretreated metastatic colorectal cancer (mCRC) patients. Pharmacogenomic analysis was performed to investigate the association
between VEGF single-nucleotide polymorphisms and clinical outcome.
PATIENTS AND METHODS: A total of 89 mCRC patients were recruited in a two-step study design; 28 were included in the dose-finding
study and 59 in the pharmacogenomic analysis. The FDR-GMB of 1000mgm
–2, bevacizumab 5mgkg
–1and CPT-11 doses ranging
from 100 to 160mgm
–2 were explored. The VEGF protein serum levels were quantified by EIA. Allelic discrimination was
performed to genotype polymorphisms in the VEGF gene.
RESULTS: CPT-11 RD was 150mgm
–2. Diarrhoea and neutropenia were the DLT. After a median follow-up of 42 months, the median
time to progression (TTP) and overall survival were 5.2 and 19.9 months, respectively. VEGF levels were significantly correlated with
VEGF-2578AA and VEGF-460CC genotypes, and a trend was observed with VEGFþ405GG genotype. The presence of any of
these genotypes correlated with a longer median TTP (8.8 vs 4.5 months, P¼0.04).
CONCLUSION: The triplet combination tested in this study is effective and well tolerated. A possible predictive role for VEGF gene
polymorphisms and baseline VEGF circulating levels is suggested.
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To date, most patients with relapsed metastatic colorectal cancer
(mCRC) receive second or further lines of systemic therapy
(Rothenberg, 2004). Overall response rate in the range of 15–25%
and survival times around 12 months have been reported,
with varying degrees of improved outcome (Maindrault-Goebel
et al, 1999; Tournigand et al, 2004). Irinotecan-based regimens
are commonly used after failure of first-line oxaliplatin/fluoro-
pyrimidine combinations (Tournigand et al, 2004). Although
bevacizumab uniformly enhanced the cytotoxic antitumour effect
of chemotherapy in the first-line setting of mCRC (Kabbinavar
et al, 2003; Hurwitz et al, 2004), at the time we initiated this study,
a limited efficacy had been reported with this agent in pretreated
mCRC patients, possibly due to the low expected activity of the
chemotherapy component (Emmanoulides et al, 2004). On these
basis, and taking into account the modest outcome achieved with
second-line FOLFIRI (Tournigand et al, 2004), we hypothesised
whether the addition of bevacizumab to an irinotecan-based
schedule without 5-fluorouracil may represent a promising
strategy.
Gemcitabine (GMB), a difluorinated analogue of deoxycytidine,
exerts its antitumour activity through inhibition of ribonucleotide
reductase and DNA synthesis (Plunkett et al, 1995). Although
prolonged exposure of this agent appeared to have superior
activity when compared with bolus administration in murine colon
tumours (Kornmann et al, 2000), several phase I/II trials of
single-agent GMB had demonstrated minimal activity in mCRC
patients (Moore et al, 1992; Mani et al, 1998; Lonardi et al, 2004).
However clinical outcomes remarkably improve when GMB is used
in combination regimens. In fact, a growing body of evidence
suggests that GMB synergistically interacts with some of the most
widely used agents in mCRC, including fluoropyrimidines
(Correale et al, 2003) and oxaliplatin (Faivre et al, 1999). In
addition, in vitro blockade of VEGF-receptor activation has proved
to enhance the efficacy of GMB (Solorzano et al, 2001).
A synergistic sequence-dependent interaction of GMB and
SN-38 has also been found in preclinical models, as the
incorporation of GMB into DNA enhances campothecin-induced
topo-1 cleavage complexes (Pourquier et al, 2002). Indeed, in
colon cancer-derived cell lines, GMB was shown to induce the
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sexpression of all topoisomerase enzymes and cytotoxicity was
more relevant when cells lines were treated with GMB and topo-
isomerase I posions within a short period of time (Richter et al,
2006).
This preclinical background has prompted the design of clinical
studies with GMB-based combinations, mainly oxaliplatin and
fluoropyrimidines, in pretreated mCRC patients (Correale et al,
2004), with interesting tumour growth control rates and a
favourable toxicity profile.
The VEGF gene expression is upregulated in colorectal cancer
and can be predictive of invasiveness, metastases, recurrence and
prognosis (George et al, 2001). Numerous single-nucleotide
polymorphisms (SNPs) in the promoter, 50- and 30-untranslated
regions have been described (Brogan et al, 1999), although their
predictive value regarding bevacizumab efficacy in mCRC remains
to be determined.
On the basis of these considerations, we initiated this pilot study
with a double aim; first, to determine the dose-limiting toxicity
(DLT), the recommended dose (RD) and preliminary evidence
of activity of this triplet combination. The second objective was
to explore the association of baseline VEGF circulating levels,
VEGF gene SNPs and clinical outcome.
PATIENTS AND METHODS
Eligibility
Eligibility criteria included age 418 years and a histologically
confirmed mCRC progressed after one prior oxaliplatin/fluoro-
pyrimidine-based chemotherapy regimen for metastatic disease.
Pre-trial disease progression was radiologically confirmed
and independently reviewed. Patients who had only received
adjuvant chemotherapy were not included. In addition, an Eastern
Cooperative Oncology Group performance status score 0–2, a life
expectancy 412 weeks, an adequate hepatic, renal and haemato-
logical function, and measurable disease by RECIST criteria
(Therasse et al, 2000) were required.
Exclusion criteria included active second malignancy, prior
anti-VEGF therapy, brain metastases, uncontrolled severe infec-
tion, major organic failure, ischaemic cardiopathy, bleeding or
clotting diatheses and requirement for systemic anticoagulation.
Pretreatment baseline evaluation included a complete medical
history, physical examination, full blood count, biochemistry
including carcinoembryonic antigen, and a CT scan of the chest,
abdomen and pelvis. During treatment, a physical examination and
blood cell counts were performed biweekly. Treatment was delayed
until recovery in case of neutrophils o1500mm
–3, platelets
o75000mm
–3 or diarrhoea or stomatitis grade 41 on the planned
day of treatment. If treatment had to be delayed for longer than
2 weeks, or any drug discontinued permanently, patients were
excluded from the study. Dose reductions of GMB and irinotecan
were allowed based upon treatment tolerability. Bevacizumab was
withheld in case of gastrointestinal perforation, grade 3–4 haemor-
rhage, uncontrolled hypertension or arterial thromboembolism.
Maintenance therapy with single-agent bevacizumab was
allowed in those patients achieving disease control after six cycles
of therapy upon investigators’ discretion.
A refractory disease was defined in those patients in whom
progressive disease to the previous line of therapy was documen-
ted as best response. Patients who achieved an objective response
(complete (CR)/partial responses (PR)) or disease stabilisation
(s.d.) but progressed during or within 3 months thereafter from
the end of that therapy were considered to have a resistant disease.
Patients’ characteristics and their outcomes were unknown to
investigators performing genetic analyses. The local institutional
review board approved the study and all patients provided written
informed consent before recruitment.
Study design and treatment
Between January 2005 and October 2008, a total of 89 mCRC
patients were enrolled in this two-step study.
Step 1: Dose-finding study
The dose-finding part of the study was designed considering the
previous RD for biweekly GMB within a multidrug regimen in
mCRC (Correale et al, 2004), the reported lack of a dose–response
effect for this agent (Mavroudis et al, 2003) and taking into
account that CPT-11 efficacy and toxicity are both dose dependent
(Abigerges et al, 1994). Thus, in the dose-finding part of the study,
GMB (1000mgm
–2 at a fixed dose rate of 10mgm
–2min
–1)
followed by irinotecan (starting dose of 100mgm
–2, with
10mgm
–2 increments) and bevacizumab (5mgkg
–1) were admi-
nistered on a biweekly basis. Consecutive cohorts of at least three
patients were recruited until the maximum tolerated dose (MTD)
was defined. If one out of three patients experienced a DLT,
a minimum of three additional patients was enrolled at the
same dose level. An MTD was defined if two out of three
patients experienced a DLT. The RD was the dose level just below
the MTD.
Toxicities were graded according to the National Cancer
Institute Common Toxicity Criteria (version 2.0). The DLTs
included grade 4 neutropenia lasting 47 days, grade 3–4 neutro-
penic fever, grade 4 thrombocytopenia, grade 3–4 haemorrhage,
grade 3–4 non-haematological toxicity, except for alopecia, nausea
or vomiting, gastrointestinal perforation and treatment delay of
44 weeks as a result of toxicity.
Step 2: Clinical and pharmacogenomic analysis
Once the irinotecan RD was established in a limited dose-finding
assessment, this cohort was further expanded in order to prospec-
tively perform an efficacy analysis and an exploratory angio-
genesis-directed pharmacogenomic profiling of the combination.
Sites of metastatic disease were radiologically re-evaluated every
8 weeks according to standard RECIST criteria unless clinically
otherwise indicated (Therasse et al, 2000). All responses were
independently reviewed and had to be confirmed X28 days after
the initial documentation of response. At the time of maximum
response, determined by serial CT scans or positron emission
tomography if clinically indicated, patients were evaluated by a
multidisciplinary team that included surgeons, medical onco-
logists, hepatologists and interventional radiologists. In this
evaluation it was ruled out whether a consolidative approach
should be attempted. These approaches consisted of surgical
removal of all macroscopic remaining disease, radiofrequency
ablation or liver radioembolisation with Yttrium
90 microspheres.
Serum samples were obtained by centrifugation at 3000r.p.m.
for 10min and stored at  801C until use. Serum levels of VEGF,
normalised by the patients platelet count, were determined using
a VEGF ELISA (R&D Systems, Minneapolis, MN, USA) according
to the manufacturer’s instructions.
VEGF gene polymorphisms (Supplementary Table 1)
were selected if a reported minor allelic frequency 40.20 in a
Caucasian population was recorded in the SNP database (http://
www.ncbi.nlm.nih.gov/SNP), and/or if the given polymorphism
may alter the function of the gene in a biologically relevant
manner.
DNA was extracted from EDTA-anticoagulated peripheral blood
using the DNAeasy Mini kit (Qiagen, Valencia, CA, USA).
Candidate SNPs were genotyped with Taqman-based real-time
PCR using the ABI Prism 7900HT Sequence Detection System
(Applied Biosystems, Foster City, CA, USA). Primers and probes
were obtained from Applied Biosystems as Assays-on-Demand
SNP genotyping product (Supplementary Table 1).
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sStatistical analysis
Descriptive statistical methodology was used to design and analyse
the dose-finding part of the study. Once the RD was achieved, the
primary study end point was response rate; secondary end points
included characterisation of time to progression (TTP), overall
survival (OS) and treatment safety. Analysis of baseline circulating
VEGF levels and VEGF gene SNPs as predictors of TTP were
evaluated at an exploratory level. A two-staged Simon accrual
design was adopted with a minimum target activity level (CRþPR)
of 20% (Tournigand et al, 2004), with the initial stage accruing
24 response-assessable patients. Early discontinuation of the study
was planned in the case of less than five responses in the first 24
patients. A minimum planned sample size of 48 evaluable patients
was chosen to better estimate efficacy, and a total of 59 patients
were recruited. The probability of erroneously concluding that the
new treatment is active (PX0.20) when it is actually ineffective
(Pp0.04) is o0.05 (a). The probability of erroneously concluding
that the treatment is ineffective (Po0.20) when is actually effective
(Pp0.04) is o0.05 (b).
The TTP and OS were calculated from the first day of treatment
to the date of first observation of progressive disease or death,
respectively. Patients who underwent consolidative procedures
after being downstaged with the use of the study regimen
were censored at that time for TTP analysis. Patients without
documented OS events were censored at last contact. Kaplan–
Meier estimates are provided for median TTP and OS, and the
log-rank or Breslow tests were applied to test the differences in
time-to-event across different genotypes. Differences in circulating
VEGF levels were evaluated using the Mann–Whitney U-test.
We estimated the false-positive report probability (FPRP) for
the observed statistically significant associations using the
methods described by Wacholder et al (2004). FPRP is the
probability of no true association between a genetic variant and a
phenotype given a statistically significant finding. It depends not
only on the observed P-value but also on both the prior probability
that the association between the genetic variant and the phenotype
is real and the statistical power of the test. In the current study,
we set the odds ratio and HR values of 2–4 as a likely threshold
value. The prior probability used was 0.25 for all SNPs. The FPRP
value for noteworthiness was set at 0.2, which indicates any finding
with an FPRP P-value of o0.2 is noteworthy.
All statistical tests were performed with the SPSS software v15.0
for Windows (SPSS Inc., Chicago, IL, USA). P-values o0.05 were
considered statistically significant.
RESULTS
Part 1: Dose-finding study
Dose-level (DL) characteristics, the type of DLTs and efficacy
results are summarised in Tables 1A and B. In the first five dose
levels, no DLT was found. DL6 was expanded to six patients due to
one dose-limiting occurrence of grade 3 asthenia. No further DLT
were observed. At DL 7 (irinotecan 160mgm
–2), two out of
three patients developed DLT: grade 3 asthenia (two patients) and
grade 3 febrile neutropenia (one patient). The RD was therefore
established at DL 6 (150mgm
–2). This dose level was subsequently
expanded with six more patients, with no further observation
of DLT.
Part 2: Clinical and pharmacogenomic analyses
Clinical analysis Once the RD and preliminary evidence of
efficacy were established, 59 additional patients were included in
the second part of the trial. Characteristics of these 59 patients are
summarised in Supplementary Tables 2 and 3. Most patients
(76.3%) received the study regimen as second line. Among them,
28 (62.2%) had received a triplet regimen up-front, (FOLFOXIRI
or FOLFOX-Cetuximab), whereas the remaining 17 patients
had received first-line therapy with FOLFOX or XELOX. In all,
31 patients (52.5%) treated with the study regimen as second
line were considered to have resistant (16 patients) or refractory
disease (15 patients). Twenty-one patients received single-agent
bevacizumab as maintenance therapy.
The toxicity profile of the combination was mild and it is
listed in Supplementary Table 4. The treatment was generally well
tolerated in the outpatient setting. The most common grade 3–4
events were haematological. Eight and ten patients had grade 3
leucopenia and grade 3 neutropenia, respectively. Grade 3–4 non-
haematological toxicities were rare and included grade 3 diarrhoea
Table 1A Irinotecan doses level and DLTs
Dose (mgm
–2) N Number of patients with DLT Type of DLT Efficacy
100–140 15 0 — 2 CR, 5 PR, 6 SD, 2 PD
150 12 1 Grade 3 asthenia. 1 CR, 4 PR, 6 SD, 1 PD
160 3 2 Grade 3 febrile neutropenia Grade 3 asthenia 1 PR, 2 SD
Abbreviations: CR¼complete response; DLT¼dose-limiting toxicity; PD¼progressive disease; PR¼partial response; SD¼stable disease.
Table 1B Worst-grade toxicity per patient
Event Level 1–5 (n¼15) Level 6 (n¼12) Level 7 (n¼3)
Leucopenia
Grade 1–2 5 5 2
Grade 3–4 1 0 1
Neutropenia
Grade 1–2 2 2 1
Grade 3–4 0 0 1
Anaemia
Grade 1–2 6 2 2
Grade 3–4 1 0 0
Thrombocytopenia
Grade 1–2 2 2 0
Grade 3–4 0 0 0
Diarrhoea
Grade 1–2 2 4 2
Grade 3–4 0 0 0
Vomiting
Grade 1–2 4 5 2
Grade 3–4 0 0 0
Asthenia
Grade 1–2 11 3 1
Grade 3–4 0 1 2
Fever
Yes 1 0 1
No 14 11 2
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sand grade 3 asthenia in 5 and 7% of the patients, respectively.
Hypertension was the most frequently reported bevacizumab-
related toxicity, being of grade 3 in 13.5% of the patients. Other
grade 3–4 bevacizumab-specific toxicities included gastro-
intestinal perforation (3.3%), VTE (1.6%) and bleeding (1.6%)
Eleven patients required hospitalisation during the study therapy
due to gastrointestinal perforation managed medically (2),
haemoptysis (1), neutropenia (5) and fever (3).
On an intent-to-treat basis, overall response rate was 45.7%,
with 25 (42.3%) PR and 2 (3.4%) CR. Overall response rate was
63.6 and 30% in patients with sensitive and resistant/refractory
disease, respectively (P¼0.059). Disease control rate (DCR; CR,
PR and SD lasting 46 months) was achieved in 32 patients
(54.2%). Sixteen patients (27.2%) achieved a sufficient down-
staging to undergo a consolidative procedure, including liver
surgery (seven patients), thoracic surgery (five patients) or liver
radioembolisation with Yttrium
90 microspheres (four patients).
After a median follow-up of 42 months (range: 10–59), the
median TTP and OS were 5.2 (95% CI: 3.4–6.8) and 19.9 months
(95% CI: 32–77), respectively.
In the univariate analysis, risk index according to Ko ¨hne
classification (Kohne et al, 2002) and DCR achievement were
significantly associated with TTP (Supplementary Table 2). A trend
was also found for response to the preceding line of therapy
(Supplementary Table 2). In addition, Ko ¨hne risk index, response
to the previous line of treatment and DCR achievement were all
associated to OS (Supplementary Table 2).
Serum VEGF levels, VEGF polymorphisms and clinical
outcome Although it remains a controversial issue, standardisation
of serum VEGF, normalised by the patients platelet count, has been
recommended (George et al, 2000), and thus we use this approach in
this study.
Baseline VEGF serum levels were significantly higher in Ko ¨hne
high-risk patients (mean±s.d., 4.42pg per 10
3 platelet±2.17pg
per 10
3 platelet) as compared with the low-risk group (mean±s.d.,
2.06pg per 10
3 platelet±1.32pg per 10
3 platelet) (P¼0.01).
VEGF levels were dichotomised into two categories around the
median value (platelet-normalised VEGF baseline levels 4 or o3)
to better describe its association with survival times. A significant
relationship was found between platelet-normalised VEGF baseline
levels and TTP (P¼0.02; Breslow test) (Figure 1A), with a median
TTP of 2.4 (0.83–3.89) months and 8.2 (5.1–11.2) months for
patients with high and low VEGF baseline levels, respectively.
A significant association was also found between platelet-normal-
ised VEGF baseline levels and OS (P¼0.034; log-rank test)
(Figure 1B), with a median OS of 5.2 (0.27–10.1) months and
21.3 (0.3–47.3) months for patients with high and low VEGF
baseline levels, respectively.
As VEGF SNPs contribute to a high variability in VEGF
circulating plasma concentrations (Watson et al, 2000), we
searched for this association in our patients cohort. The VEGF
genotype frequencies are shown on Supplementary Table 5.
Genotype frequencies of all SNPs followed the Hardy–Weinberg
equilibrium. Platelet-normalised serum circulating VEGF baseline
levels were significantly lower in VEGF-2578AA and VEGF-460CC
carriers (P¼0.008) and a trend was also observed for
VEGFþ405GG genotype (Supplementary Figures 1A–C). These
results led us to further investigate the correlation between
low-VEGF level-associated SNPs and clinical outcome. Patients
VEGF high (n=16)
Any favourable VEGF genotype (n=28)
None favourable VEGF genotype (n=31)
VEGF high (n=16)
VEGF low (n=16)
VEGF low (n=16)
P=0.020, Breslow test
P=0.043, log-rank test
P<0.001, Breslow test
3 favourable factors
(n=11)
2 favourable factors
(n=13)
1 favourable factor
(n=22)
No favourable factor
(n=13)
P=0.034, log-rank test
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Figure 1 Kaplan–Meier curves for time to progression (TTP) (A) and overall survival (OS) (B) according to circulating vascular endothelial growth factor
(VEGF) serum levels and according to the number of VEGF favourable genotypes (C) TTP outcome stratified on basis of the number of favourable clinical
and molecular factors (D).
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scarrying the VEGF-2578AA genotype had a longer TTP than those
with the combined CA and CC genotypes (8.8 vs 5 months;
P¼0.080; Supplementary Figure 2A). Similar data were found for
the VEGF-460CC genotype (9.6 vs 4.5 months; P¼0.054; Supple-
mentary Figure 2B). There was also a trend for a longer TTP
according to VEGFþ405 polymorphism (P¼0.13; Supplementary
Figure 2C). Patients harbouring at least one of these genotypes
(VEGF-2578 AA, VEGF-460 CC or VEGFþ405 GG) showed a
significantly longer median TTP than patients possessing none of
them (8.8 vs 4.5 months; P¼0.043; Figure 1C).
In an attempt to classify different risk groups in this population,
a predictive-risk score was calculated according to the number of
favourable clinical (Ko ¨hne low-risk category and DCR achieve-
ment) and molecular (any favourable VEGF genotype) factors.
This analysis rendered four different risk groups, with a median
TTP ranging from 2.3 months (95% CI: 0.49–4.25) to 11.4 months
(95% CI: 8.5–14.4) corresponding to the groups with none and
three favourable factors, respectively (Figure 1D).
In the multivariate model, including the VEGF favourable
genotypes and relevant clinical factors according to the univariate
analysis (Ko ¨hne risk index and DCR), the presence of any
favourable VEGF genotype and DCR achievement were both
significantly associated with TTP (Table 2). The FPRP was 0.163
for patients carrying any favourable VEGF genotype, indicating
noteworthiness.
DISCUSSION
To our knowledge, this is the first study to report mature results on
the combination of GMB, irinotecan and bevacizumab in
oxaliplatin/fluoropyrimidines pretreated mCRC. Although it is a
heterogeneous group, with most patients receiving the regimen as
second line and some as an even later line, if we take into account
the type of previous systemic therapies and the high percentage of
patients considered to have a truly resistant or refractory disease,
our results seem to be encouraging and compare favourably with
other irinotecan-based regimens in oxaliplatin-pretreated mCRC
(Recchia et al, 2004; Tournigand et al, 2004; Bidard et al, 2009).
Furthermore, they overlap with those achieved when bevacizumab
is combined with a more active partner than 5-FU (Giantonio et al,
2007; Lievre et al, 2009) and with other reported GMB-based
schedules (Correale et al, 2004, 2005; Ziras et al, 2006; Lopes et al,
2007; Bitossi et al, 2008; Merl et al, 2009). Although 27% of the
patients underwent a consolidative procedure, this finding should
be viewed with caution, as the trial was not specifically designed to
rule out the resectability rate achieved with this combination.
Dose-limiting toxicities for the combination included grade 3
asthenia and neutropenia. At the RD, toxicity profile was mild.
Altogether, 12% of the patients required hospitalisation, but
toxicities were uneventfully managed and no toxic deaths were
reported. The addition of bevacizumab did not significantly
change the side effect profile associated with GMB and CPT-11
(Kakolyris et al, 2002; Nishio et al, 2005). The low incidence of
bevacizumab-specific toxicities encountered in this trial and
the previously reported lack of PK/PD interactions between
irinotecan and bevacizumab (Denlinger et al, 2009) may be partly
responsible for these findings. Nevertheless, these results should
be viewed with caution, as recent work has suggested
that UGT1A1-driven irinotecan dose-escalation studies may more
accurately define the precise dosage for this agent (Goetz et al,
2007).
To date, most of the tested biomarkers have failed to
discriminate patients more likely to benefit from bevacizumab-
containing regimens. Assessment of baseline VEGF circulating
levels has yielded conflicting results (Burstein et al, 2008; Kopetz
et al, 2010). We initially decided to use serum, instead of plasma,
to measure VEGF baseline levels. Plasma VEGF levels are close to
the lower limits of detection of the currently available ELISA and,
subsequently, serum assessments may provide a greater sensitivity
(George et al, 2000). Several studies demonstrated that paired
serum and plasma VEGF levels correlated in mCRC, and both of
them increase with advanced disease stage (Banks et al, 1998). In
this study, significantly longer median survival times were found
in patients with low baseline VEGF levels. Interestingly, low VEGF
level-associated SNPs were also correlated with a better clinical
outcome in terms of TTP. Similar results were obtained for both,
the VEGF-2578A4C and the VEGF-460T4C polymorphisms, in
agreement with a previously described strong linkage disequili-
brium between both loci. In vitro work has also linked the VEGF-
2578AA genotype with a decreased VEGF secretion in peripheral
blood mononuclear cells (Shahbazi et al, 2002) and a lower
immunohistochemical VEGF expression in cancer specimens
(Schneider et al, 2008). Our results show that patients harbouring
the VEGF-2578AA genotype achieve an almost two-fold longer
TTP compared with alternative genotypes. Similar findings have
been reported in metastatic breast cancer patients treated with
bevacizumab-based schedules, with VEGF-2578AA carriers show-
ing longer survival times compared with the VEGF-2578CAþCC
genotype (Schneider et al, 2008). The VEGF-2578CC genotype has
also been associated with an inferior median OS compared with
alternative genotypes in mCRC patients treated with irinotecan-
based chemotherapy and bevacizumab in the first-line setting
(Koutras et al, 2010).
There may be several potential limitations in these findings. The
limited sample size, the exploratory nature of the pharmaco-
genomic analysis and the complex biological network involved in
tumour angiogenesis make it mandatory to confirm these data
in larger, prospectively designed clinical trials. Furthermore,
Ko ¨hne low- and intermediate-risk patients were more likely to
have low VEGF baseline levels compared with the high-risk group,
and subsequently, a potential confounding interaction between
these variables cannot be definitively ruled out. Indeed, VEGF
levels have been advocated as a prognostic rather than a predictive
factor by other authors (Bernaards et al, 2010).
In conclusion, this study suggests that the combination of GMB,
irinotecan and bevacizumab may be a valid alternative for
oxaliplatin/fluoropyrimidines-pretreated mCRC patients. A further
insight into the possible role of VEGF gene SNPs as surrogate
markers of bevacizumab-based therapy efficacy seems warranted.
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Table 2 Adjusted Cox multivariate analysis for TTP
Factor Variable
Hazard
ratio 95% CI P-value
Any favourable VEGF genotype Yes 1.0 — 0.017
No 2.3 1.1–4.5 —
DCR Yes 1 — o0.001
No 79.4 9.9–630.9 —
Abbreviations: CI¼confidence interval; DCR¼disease control rate; TTP¼time to
progression; VEGF¼vascular endothelial growth factor. In the multivariate model,
VEGF favourable genotypes and the relevant clinical factors according to the
univariate analisis (Ko ¨hne risk index and DCR) have been included.
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